COVID-19 News & Education
Latest articles from our blog
Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
BURLINGTON, N.C., June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.Read more about Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
View our latest news about advancements in health science, COVID-19, and more.
Labcorp's COVID-19 PCR Testing
Average Time to Result from Specimen Pickup
Molecular Tests Performed
Molecular Test Capacity Per Day*
Antibody Tests Performed
Antibody Test Capacity Per Day*
Tests Offered with No Upfront Costs**
Stats updated as of June 30, 2022. COVID-19 volumes are U.S. and Canada volumes and are consistent with the figures provided in the company’s quarterly financial results. Prior volumes published on the website were U.S. only. Future COVID-19 test volumes will be updated quarterly after the release of Labcorp’s quarterly earnings results.
*Capacity numbers are subject to sufficient labor, equipment and supplies
**Labcorp remains committed to providing access to COVID-19 tests without incurring upfront costs for as many people as possible. The cost of our COVID-19 test is set by the Centers for Medicare and Medicaid Services. For people with insurance, Labcorp bills the insurance plans or government agency for reimbursement. For individuals without insurance or health care coverage, the cost of the test is billed to the individual by Labcorp at the same rate paid by Medicare to laboratories for COVID testing. A $6 non-refundable physician fee is charged for the IgG antibody test if it is requested through Labcorp.com.
Tracking COVID-19 Variants
Labcorp has been regularly tracking variants of the virus throughout the pandemic. The sensitivity of our PCR test is not impacted by these variants. We have been working with the Centers for Disease Control and Prevention (CDC) to provide sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. Our tests remain effective against variants like Omicron and Delta. This is because they are designed to identify segments of the genetic code that are the least likely to mutate. For more information on variants, see our Viral Variation 101 post or read our Guide to Variants.
Total number of samples sequenced
402,000 as of June 30, 2022
Data covers the U.S. including the District of Columbia and Puerto Rico
Labcorp PCR Test performance confirmed
Alpha (B.1.1.7, Q.1-Q.8)
Beta (B.1.351, B.1.351.2, B.1.351.3)
Epsilon (B.1.427, B.1.429)
Gamma (P.1, P.1.1, P.1.2)
Omicron (B.1.1.529, BA.2, BA.4, BA.5)